Navigation Links
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Date:5/4/2009

nageable. Triglycerides and cholesterol were not elevated and had no negative impact on the cardiovascular safety profile. Hair growth (hirsutism) was observed in 5% of patients. Otherwise the safety profile was similar to placebo.

  • In study LX211-01 the 0.4 mg/kg BID dose fully met the primary endpoint of superiority to placebo at both weeks 16 (p=0.008) and week 24 (p=0.027) for mean change from baseline in vitreous haze, a validated measure of inflammation of the posterior segment of the eye. The magnitude of the effect was >1 step change from baseline, demonstrating a clinically relevant benefit.

  • In study LX211-02 the 0.4 mg/kg BID dose showed a reduction by 50% vs. placebo in rate of recurrence of inflammation at 6 months using a pre-specified analysis that accounted for data censoring due to non-efficacy-related discontinuations. This reduction was statistically significant (p=0.045), thus confirming the positive results from LX211-01.

  • In study LX211-03, treated patients reduced the cellular response in the front of the eye from an average of more than 25 white blood cells per high power microscopic field to an average of 6 to 10 cells per high power field. However, placebo-treated patients also improved in this study and it was therefore not possible to show that LX211 was effective for this rare subset of uveitis patients, those with refractory disease in the anterior portion of the eye.

    The LUMINATE program was conducted under the sponsorship of Lux Biosciences.


    '/>"/>

  • Contact: Joan Kureczka
    JKureczka@comcast.net
    415-821-2413
    Kureczka/Martin Associates
    Source:Eurekalert

    Page: 1 2 3 4

    Related biology technology :

    1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
    2. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
    3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
    4. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
    5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
    6. The first DFG research centers to be funded for another 4 years
    7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
    8. Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll
    9. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
    10. United Therapeutics Reports First Quarter 2009 Financial Results
    11. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
    (Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
    (Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
    (Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
    Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
    ... Keck Graduate Institute,s (KGI) Biotechnology Entrepreneurship program today announced ... Dec. 8, 2008. , , ... individual investors who fund early-stage, technology and high-growth companies in ... in becoming angel investors. The educational session begins at ...
    ... disease,diagnostics market has demonstrated sustained growth due to ... occurring in the,market, promoting technology and product integration. ... policies for autoimmune diagnostic tests,persists, posing a challenge ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...
    ... JOSE, Calif., Nov. 21 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of venous reflux disease, today announced its,plans ... to be,held December 2-3, 2008, at The New York Palace ... Brian Farley, President and Chief Executive,Officer. , ...
    Cached Biology Technology:KGI Entrepreneur Program Hosts Angel Investing Educational Meeting 2Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market 2Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market 3
    (Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
    (Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
    (Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
    Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
    ... found for the first time in a variety of freshwater ... , According to experts at the Aquatic Animal Health ... septicemia virus (VHSV), which causes fatal anemia and hemorrhaging in ... poses no threat to humans. , In May ...
    ... at the University of California, San Diego and three other ... inter-related responses that cells use to avoid becoming diseased or ... The group led by UCSD bioengineering professor Trey Ideker describe ... of gene control that is triggered by chemical damage to ...
    ... Iranian scientists have linked a chemical that plays an ... damage and male infertility, the 22nd annual conference of ... , Dr Iraj Amiri, embryology laboratory director at the ... years nitric oxide (NO) has been recognised as a ...
    Cached Biology News:Cornell researchers find serious fish virus in Northeast for first time 2Heal thyself: Systems biology model reveals how cells avoid becoming cancerous 2Heal thyself: Systems biology model reveals how cells avoid becoming cancerous 3Study links high levels of nitric oxide to infertility and sperm DNA damage 2
    ... Kit ADAM17 Activity Kit TNF-α Converting Enzyme ... FROM LIGHT. AVOID FREEZE/THAW CYCLES. The InnoZyme™ ... sensitive assay designed to measure human TACE ... and for screening enzyme inhibitors. An Anti-Human ...
    ... GELase™ Agarose Gel-Digesting Preparation contains a unique ... simple, quantitative recovery of intact DNA and ... gels following electrophoresis in TAE, TBE, MOPS, ... digested directly in the TAE, TBE, MOPS, ...
    ... Premixed solution for high PCR specificity ... the combination of enzyme with unique ... nonspecific amplification provided by the ... handling convenient Master Mix and ...
    Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
    Biology Products: